0001209191-21-006934.txt : 20210202 0001209191-21-006934.hdr.sgml : 20210202 20210202183520 ACCESSION NUMBER: 0001209191-21-006934 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210129 FILED AS OF DATE: 20210202 DATE AS OF CHANGE: 20210202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Snisarenko John CENTRAL INDEX KEY: 0001783264 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39112 FILM NUMBER: 21583213 MAIL ADDRESS: STREET 1: C/O ALIMERA SCIENCES, INC. STREET 2: 6120 WINDWARD PARKWAY, SUITE 290 CITY: ALPHARETTA STATE: GA ZIP: 30005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Oyster Point Pharma, Inc. CENTRAL INDEX KEY: 0001720725 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 811030955 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 BUSINESS PHONE: (609) 382-9032 MAIL ADDRESS: STREET 1: 202 CARNEGIE CENTER STREET 2: SUITE 109 CITY: PRINCETON STATE: NJ ZIP: 08540 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-01-29 0 0001720725 Oyster Point Pharma, Inc. OYST 0001783264 Snisarenko John C/O OYSTER POINT PHARMA, INC. 202 CARNEGIE CENTER, SUITE 109 PRINCETON NJ 08540 0 1 0 0 Chief Commercial Officer Common Stock 2021-01-29 4 A 0 11222 0.00 A 18222 D Employee Stock Option (Right to Buy) 18.77 2021-01-29 4 A 0 50500 0.00 A 2031-01-28 Common Stock 50500 50500 D Represents a grant of restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. 25% of the RSUs vest on January 29, 2022 and the remainder vest annually thereafter on the same day of the month as the grant date over the following 3 years, subject to the Reporting Person's continuous service to the Issuer through each such date. Options granted on January 29, 2021 under the Oyster Point Pharma, Inc. 2019 Equity Incentive Plan. 25% of the options shall vest and become exercisable on January 29, 2022 and one thirty-sixth (1/36) of the remaining options shall vest monthly thereafter on the same day of the month (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person's continuous service to the Issuer through each such date. /s/ Brandon Fenn, Attorney-in-Fact 2021-02-02